Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pelthos Therapeutics (PTHS) Interest Expenses (2024 - 2025)

Pelthos Therapeutics has reported Interest Expenses over the past 2 years, most recently at $1.3 million for Q4 2025.

  • Quarterly results put Interest Expenses at $1.3 million for Q4 2025, up 1116.67% from a year ago — trailing twelve months through Dec 2025 was $2.7 million (up 1712.69% YoY), and the annual figure for FY2025 was $3.0 million, up 283.21%.
  • Interest Expenses for Q4 2025 was $1.3 million at Pelthos Therapeutics, down from $1.3 million in the prior quarter.
  • Over the last five years, Interest Expenses for PTHS hit a ceiling of $1.3 million in Q3 2025 and a floor of $1816.0 in Q1 2025.